PASG
Passage Bio Inc.
$7.38
-$0.16(-2.12%)
66
Overall
--
Value
66
Tech
--
Quality
Market Cap
$23.11M
Volume
23.62K
52W Range
$0.26 - $7.75
Target Price
$59.25
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | -- | -- | -- | -- | $1.0M | ||
| Total Revenue | -- | -- | -- | -- | $1.0M | ||
| GROSS PROFIT | |||||||
| Gross Profit | -- | -- | -- | -- | $1.0M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $112.9M | $185.7M | $135.4M | $103.0M | $65.2M | ||
| Research & Development | $82.8M | $125.7M | $89.1M | $61.4M | $40.2M | ||
| Research Expense | $81.8M | $117.7M | $86.1M | $61.4M | $40.2M | ||
| Selling, General & Administrative | $30.1M | $60.1M | $49.3M | $41.6M | $25.0M | ||
| General & Administrative Expenses | $30.1M | $60.1M | $49.3M | $41.6M | $25.0M | ||
| Salaries & Wages | -- | -- | -- | $10.9M | $5.8M | ||
| Depreciation & Amortization | -- | $1.5M | $3.7M | $3.7M | $3.1M | ||
| Depreciation & Amortization | -- | $1.5M | $3.7M | $3.7M | $3.1M | ||
| Other Operating Expenses | $600.0K | $3.4M | $5.1M | $5.4M | $5.6M | ||
| OPERATING INCOME | |||||||
| Operating income | $-112.9M | $-185.7M | $-138.4M | $-108.4M | $-70.4M | ||
| EBITDA | $-111.1M | $-176.2M | $-131.7M | $-99.3M | $-61.7M | ||
| NON-OPERATING ITEMS | |||||||
| Intinc | $670.0K | $343.0K | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $670.0K | $343.0K | $-2.3M | -- | -- | ||
| Gain on Sale of Securities | -- | $343.0K | $2.3M | -- | -- | ||
| Other Income/Expense | -- | $-343.0K | $-731.0K | $-6.3M | $-5.6M | ||
| Other Special Charges | -- | -- | $2.3M | $6.3M | $5.6M | ||
| SPECIAL ITEMS | |||||||
| Special Income Charges | -- | -- | -- | $-5.4M | $-5.2M | ||
| Impairment of Capital Assets | -- | -- | -- | $5.4M | $5.2M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-111.9M | $-177.7M | $-135.4M | $-103.0M | $-64.8M | ||
| Pre-Tax Income | $-112.2M | $-185.4M | $-136.1M | $-102.1M | $-64.8M | ||
| NET INCOME | |||||||
| Net Income | $-112.2M | $-185.4M | $-136.1M | $-102.1M | $-64.8M | ||
| Net Income (Continuing Operations) | $-112.2M | $-185.4M | $-136.1M | $-102.1M | $-64.8M | ||
| Net Income (Discontinued Operations) | $-112.2M | $-185.4M | $-136.1M | $-102.1M | $-64.8M | ||
| Net Income (Common Stockholders) | $-112.2M | $-185.4M | $-136.1M | $-102.1M | $-64.8M | ||
| Normalized Income | -- | $-146.5M | -- | -- | $-56.4M | ||
| TOTALS | |||||||
| Total Expenses | $112.9M | $185.7M | $135.4M | $103.0M | $65.2M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $1.9M | $2.7M | $2.7M | $2.7M | $60.4M | ||
| Average Shares Outstanding (Diluted) | $1.9M | $2.7M | $2.7M | $2.7M | $60.4M | ||
| Shares Outstanding | $2.7M | $2.7M | $2.7M | $2.8M | $62.1M | ||
| Basic EPS | $-58.2 | $-69.6 | $-50 | $-37.2 | $-1.07 | ||
| Basic EPS (Continuing Operations) | $-58.2 | $-69.6 | $-50 | $-37.2 | $-1.07 | ||
| Diluted EPS | $-58.2 | $-69.6 | $-50 | $-37.2 | $-1.07 | ||
| Diluted EPS (Continuing Operations) | -- | $-69.6 | $-50 | $-37.2 | $-1.07 | ||
| OTHER METRICS | |||||||
| Development Expense | $1.0M | $8.0M | $3.0M | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | $-463.0K | -- | ||
| Other Gand A | $30.1M | $60.1M | $49.3M | $41.6M | $25.0M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | $3.2M | $2.5M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PASG | $7.38 | -2.1% | 23.62K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |